Table 1 Baseline demographic and clinical characteristics of the patients.

From: Prediction of post-treatment retinal sensitivity by baseline retinal perfusion density measurements in eyes with branch retinal vein occlusion

Eyes/patients, n/n8/8
Age, years70 ± 2.0
12 months number of intravitreal ranibizumab injections4.4 ± 2.4
Perfusion density (1 M), %28 ± 12
Retinal sensitivity, dB9.6 ± 7.6
  1. The data are presented as the mean ± standard deviation, or number, as appropriate.